⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRA News
MIRA Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
MIRA
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
accessnewswire.com
MIRA
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
accessnewswire.com
MIRA
Form 8-K
sec.gov
MIRA
Form 8-K
sec.gov
MIRA
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
accessnewswire.com
MIRA
Form 8-K
sec.gov
MIRA
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
accessnewswire.com
MIRA
Form 8-K
sec.gov
MIRA
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
accessnewswire.com
MIRA